Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1325P - Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)

Date

16 Sep 2021

Session

ePoster Display

Topics

Clinical Research;  Cancer Biology;  Cancer in Special Situations/ Populations

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Frank Griesinger

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

F. Griesinger1, M. Sebastian2, W. Brückl3, H. Hummel4, B. Jaeschke5, J. Kern6, C. Schumann7, C. Wesseler8, M. Jänicke9, A. Fleitz9, S. Zacharias10, A. Hipper11, A. Groth11, W. Weichert12, S. Dörfel13, V. Petersen14, J. Schröder15, J. Wilke16, W.E.E. Eberhardt17, M. Thomas18

Author affiliations

  • 1 Pius-hospital Oldenburg, University of Oldenburg, 26121 - Oldenburg/DE
  • 2 Medizinische Klinik Ii, Hämatologie/onkologie, Universitätsklinikum Frankfurt, 60590 - Frankfurt/DE
  • 3 Innere Medizin Iii - Schwerpunkt Pneumologie, Klinikum Nürnberg Nord, 90419 - Nürnberg/DE
  • 4 Interdisziplinäres Studienzentrum, Universitätsklinikum Würzburg, 97078 - Würzburg/DE
  • 5 Medizinische Klinik 3, Helios Dr. Horst Schmidt Kliniken Wiesbaden, 61599 - Wiesbaden/DE
  • 6 Pneumologie & Beatmungsmedizin, Klinikum Würzburg Mitte Missioklinik, 97074 - Würzburg/DE
  • 7 Klinik Für Pneumologie, Thoraxonkologie, Schlaf- Und Beatmungsmedizin, Klinikverbund Allgäu, 87509 - Immenstadt/DE
  • 8 Klinikum Harburg Pneumologie, Asklepios Tumorzentrum Hamburg, 21075 - Hamburg/DE
  • 9 Clinical Epidemiology And Health Economics, iOMEDICO, 79106 - Freiburg im Breisgau/DE
  • 10 Statistics, iOMEDICO, 79106 - Freiburg im Breisgau/DE
  • 11 Project Management, AIO-Studien-gGmbH, 14057 - Berlin/DE
  • 12 Institute Of Pathology, Technische Universität München, 81675 - Munich/DE
  • 13 Medical Oncology, Onkologische Gemeinschaftspraxis, 01127 - Dresden/DE
  • 14 Medical Oncology, Onkologische Schwerpunktpraxis - Dr. Volker Petersen, 89522 - Heidenheim an der Brenz/DE
  • 15 Medical Hematology / Oncology, Gemeinschaftspraxis für Hämatologie und internistische Onkologie, 45468 - Mülheim a.d.R./DE
  • 16 Medical Hematology / Oncology, Schwerpunktpraxis Hämatologie und Internistische Onkologie, 90766 - Fürth/DE
  • 17 Westdeutsches Tumorzentrum, Universitätsklinikum Essen, 45147 - Essen/DE
  • 18 Thoracic Oncology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1325P

Background

Treatment for metastatic non-small cell lung cancer (NSCLC) stratified according to biomarker testing results was shown in clinical trials to have beneficial outcomes (out). Whether these improvements carry over into real-world routine therapy is of great interest for patients (pts) and physicians. Here we used the prospective, national clinical research platform CRISP to compare patient characteristics (chr) and out of pts with PD-L1 TPS≥50% tumours treated with checkpoint inhibitor monotherapy (CPI) who are deemed either potentially study-eligible (se) or non-study-eligible (n-se).

Methods

CRISP (NCT02622581) is a prospective, observational, open, multicentre, interdisciplinary clinical research platform that collects data on all (sequential) treatments, patient and tumour chr, biomarker testing, clinical and patient-reported out in ∼180 hospitals and practices in Germany. Currently 6300+ pts were recruited, who will be followed until death or end of project. Data from 493 pts with PD-L1 TPS≥50% recruited between 12/2015 and 06/2019 and receiving CPI as 1st-line treatment was analysed. Pts were deemed se if they had the following chr: ECOG=0-1, Stage IV, no brain metastases, no HIV or second tumour and no prior (neo-)adjuvant therapies.

Results

Of 473 analysed pts 191 pts were potentially se in reflection of inclusion criteria for clinical trials KEYNOTE 42 and 24, 282 pts were n-se representing the real-world pts population. Although both groups are similar in age (median 68 years, both) and CR/PR rates were comparable (1%[se] vs. 2%[n-se] and 21% vs. 22%) as well as rates of stopped treatments because of toxicity (10%, both), potentially se pts. had a longer PFS (10.0 months, 95% CI: 7.6-15.2 vs. 7.9 months, 95% CI: 6.0-10.6) and OS (23.3 months, 95% CI: 16.5-26.1 vs. 20.2 months, 95% CI: 15.9-26.2) than potentially n-se pts.

Conclusions

In recent years the use of CPI monotherapy in PD-L1 TPS≥50% pts increased in Germany, resulting in improved treatment out. Potentially study-eligible pts are profiting more than potentially non-study-eligible pts. The impact of CPI combination therapies or treatment without CPI on both pts groups, will be subject of future analyses.

Clinical trial identification

NCT02622581; Actual Study Start Date: December 2015.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH.

Funding

AIO-Studien-gGmbH.

Disclosure

F. Griesinger: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Invited Speaker: Siemens; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: Takeda; Financial Interests, Institutional, Research Grant: Siemens; Financial Interests, Institutional, Research Grant: Amgen. M. Sebastian: Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: AbbVie; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: BioNTech; Financial Interests, Personal, Invited Speaker: CureVac; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Tesaro; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Tesaro. W. Brückl: Financial Interests, Personal, Full or part-time Employment: Klinikum Nürnberg; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Chugai; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Licensing Fees: Stratifyer; Financial Interests, Personal, Licensing Fees: Siemens Healthcare; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Eli Lilly. H. Hummel: Financial Interests, Personal, Invited Speaker: Janssen-Cilag; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: BMS. J. Kern: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Amgen. C. Schumann: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche. C. Wesseler: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly. W. Weichert: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Speaker’s Bureau: Takeda; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Speaker’s Bureau: Amgen; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Speaker’s Bureau: Astellas; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Advisory Board: Illumina; Financial Interests, Personal, Speaker’s Bureau: Illumina; Financial Interests, Personal, Advisory Board: Siemens; Financial Interests, Personal, Speaker’s Bureau: Siemens; Financial Interests, Personal, Advisory Board: Agilent; Financial Interests, Personal, Speaker’s Bureau: Agilent; Financial Interests, Personal, Advisory Board: Molecular Health; Financial Interests, Personal, Speaker’s Bureau: Molecular Health. J. Schröder: Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Clovis Oncology GmbH; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: AOP; Financial Interests, Personal, Advisory Role: Searchlight; Financial Interests, Personal, Advisory Role: Pharma Partner; Financial Interests, Personal, Advisory Role: MediXline GmbH; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: HE Research GmbH; Financial Interests, Personal, Advisory Role: Octapharma; Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: iOMEDICO; Non-Financial Interests, Personal, Member: Deutsche Krebsgesellschaft; Non-Financial Interests, Personal, Member: DGHO; Non-Financial Interests, Personal, Member: ESMO; Non-Financial Interests, Personal, Member: BNHO; Non-Financial Interests, Personal, Member: WINHO; Non-Financial Interests, Personal, Member: AKS; Non-Financial Interests, Personal, Member: ASCO. W.E.E. Eberhardt: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: AbbVie; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Janssen Cilag; Financial Interests, Personal, Invited Speaker: Baumgart Consult; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: AbbVie. M. Thomas: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Institutional, Research Grant: Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.